| Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for … JJ Morigi, PD Stricker, PJ van Leeuwen, R Tang, B Ho, Q Nguyen, ... Journal of nuclear medicine 56 (8), 1185-1190, 2015 | 631 | 2015 |
| [177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial MS Hofman, L Emmett, S Sandhu, A Iravani, AM Joshua, JC Goh, ... The Lancet 397 (10276), 797-804, 2021 | 615 | 2021 |
| Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial WP Fendler, J Calais, M Eiber, RR Flavell, A Mishoe, FY Feng, ... JAMA oncology 5 (6), 856-863, 2019 | 581 | 2019 |
| The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study PJ Roach, R Francis, L Emmett, E Hsiao, A Kneebone, G Hruby, T Eade, ... Journal of Nuclear Medicine 59 (1), 82-88, 2018 | 368 | 2018 |
| Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy L Emmett, K Willowson, J Violet, J Shin, A Blanksby, J Lee Journal of medical radiation sciences 64 (1), 52-60, 2017 | 343 | 2017 |
| Prospective evaluation of 68Gallium‐prostate‐specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer PJ van Leeuwen, L Emmett, B Ho, W Delprado, F Ting, Q Nguyen, ... BJU international 119 (2), 209-215, 2017 | 316 | 2017 |
| 68Ga‐PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment PJ van Leeuwen, P Stricker, G Hruby, A Kneebone, F Ting, B Thompson, ... BJU international 117 (5), 732-739, 2016 | 311 | 2016 |
| E-PSMA: the EANM standardized reporting guidelines v1. 0 for PSMA-PET F Ceci, DE Oprea-Lager, L Emmett, JA Adam, J Bomanji, J Czernin, ... European journal of nuclear medicine and molecular imaging 48, 1626-1638, 2021 | 235 | 2021 |
| The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the … L Emmett, J Buteau, N Papa, D Moon, J Thompson, MJ Roberts, K Rasiah, ... European urology 80 (6), 682-689, 2021 | 230 | 2021 |
| Brown adipose tissue exhibits a glucose-responsive thermogenic biorhythm in humans P Lee, R Bova, L Schofield, W Bryant, W Dieckmann, A Slattery, ... Cell metabolism 23 (4), 602-609, 2016 | 193 | 2016 |
| Treatment outcomes from 68Ga-PSMA PET/CT–informed salvage radiation treatment in men with rising PSA after radical prostatectomy: prognostic value of a negative PSMA PET L Emmett, PJ van Leeuwen, R Nandurkar, MJ Scheltema, T Cusick, ... Journal of Nuclear Medicine 58 (12), 1972-1976, 2017 | 183 | 2017 |
| Rapid modulation of PSMA expression by androgen deprivation: serial 68Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen … L Emmett, C Yin, M Crumbaker, G Hruby, A Kneebone, R Epstein, ... Journal of Nuclear Medicine 60 (7), 950-954, 2019 | 173 | 2019 |
| Results of a prospective phase 2 pilot trial of 177Lu–PSMA-617 therapy for metastatic castration-resistant prostate cancer including imaging predictors of treatment response … L Emmett, M Crumbaker, B Ho, K Willowson, P Eu, L Ratnayake, ... Clinical genitourinary cancer 17 (1), 15-22, 2019 | 164 | 2019 |
| Reversible regional wall motion abnormalities on exercise technetium-99m–gated cardiac single photon emission computed tomography predict high-grade angiographic stenoses L Emmett, RM Iwanochko, MR Freeman, A Barolet, DS Lee, M Husain Journal of the American College of Cardiology 39 (6), 991-998, 2002 | 156 | 2002 |
| Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial GV Long, RPM Saw, S Lo, OE Nieweg, KF Shannon, M Gonzalez, ... The Lancet Oncology 20 (7), 961-971, 2019 | 153 | 2019 |
| FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma AC Tan, L Emmett, S Lo, V Liu, R Kapoor, MS Carlino, AD Guminski, ... Annals of Oncology 29 (10), 2115-2120, 2018 | 142 | 2018 |
| 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study WP Fendler, J Calais, M Allen-Auerbach, C Bluemel, N Eberhardt, ... Journal of Nuclear Medicine 58 (10), 1617-1623, 2017 | 141 | 2017 |
| A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). GV Long, V Atkinson, AM Menzies, S Lo, AD Guminski, MP Brown, ... Journal of Clinical Oncology 35 (15_suppl), 9508-9508, 2017 | 136 | 2017 |
| TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer … MS Hofman, L Emmett, J Violet, A Y. Zhang, NJ Lawrence, M Stockler, ... BJU international 124, 5-13, 2019 | 125 | 2019 |
| Platelet activation in acute pulmonary embolism T Chung, D Connor, J Joseph, L Emmett, R Mansberg, M Peters, D Ma, ... Journal of Thrombosis and Haemostasis 5 (5), 918-924, 2007 | 114 | 2007 |
